Isentress Film Coated Tablets 400 mg

USDailyMed:Raltegravir AU:B3 J05AJ01(WHO) CA:℞-onlyUK:POM(Prescription only)US:℞-onlyEU:Rx-only N-(4-Fluorobenzyl)-5-hydroxy-1-methyl-2-(2-{[(5-methyl-1,3,4-oxadiazol-2-yl)carbonyl]amino}-2-propanyl)-6-oxo-1,6-dihydro-4-pyrimidinecarboxamide 518048-05-0Y 54671008 DB06817 16445111Y 22VKV8053U D06676as salt:D07133 CHEBI:82960 ChEMBL254316Y 471309 RLT (PDBe,RCSB PDB) DTXSID2048660 Interactive image Cc1nnc(o1)C(=O)NC(C)(C)C\3=N\C(C(=O)NCc2ccc(F)cc2)=C(\O)C(=O)N/3C InChI=1S/C20H21FN6O5/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30)YKey:CZFFBEXEKNGXKS-UHFFFAOYSA-NY Raltegravir, sold under the brand nameIsentress, is anantiretroviral medicationused, together with othermedication, to treatHIV/AIDS.It may also be used, as part ofpost-exposure prophylaxis, to prevent HIV infection following potential exposure.It is taken by mouth. Common side effects include trouble sleeping, feeling tired,nausea,high blood sugar, andheadaches.Severe side effects may includeallergic reactionsincludingStevens–Johnson syndrome,muscle breakdown, andliver problems.It is unclear if use duringpregnancyorbreastfeedingis safe.Raltegravir is anHIV integrase strand transfer inhibitorwhich blocks the functioning ofHIV integrasewhich is needed forviral replication. Raltegravir was approved for medical use in the United States in 2007.It is on theWorld Health Organization's List of Essential Medicines.Lamivudine/raltegravir, acombinationwithlamivudine, is also available.